Shots:
- AstraZeneca has shared P-III (MATTERHORN) trial data assessing perioperative Imfinzi + FLOT (n=474) vs PBO + FLOT (n=474) in 948 pts with stage II-IVA G/GEJ cancers at ASCO 2025
- Pts received Imfinzi (1500mg) + FLOT or PBO + FLOT for Q4W × 2 cycles before surgery followed by Imfinzi (2 cycles with FLOT CT + 10 cycles as monotx.) or PBO for Q4W × 12 cycles
- At interim analysis, trial showed reduced risk of disease progression, recurrence, or death by 29%, with mEFS not reached vs 32.8mos.; EFS rate was 78.2% vs 74% at 1yr. & 67.4% vs 58.5% at 2yrs. OS trend was favorable (2EP; mOS: not reached vs 47.2mos.) & will be further assessed; data was published in The NEJM
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports the CHMP’s Positive Opinion for Perioperative Imfinzi to Treat Muscle-Invasive Bladder Cancer (MIBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
